3D Medicines Inc. is a leading innovative biopharmaceutical company and committed to the development and commercialization of next generation of immuno-oncology (I/O) therapies with differentiated clinical benefit in response to the trend of treating cancer as a chronic disease. The mission is to help prolong the survival of cancer patients and improve their quality of life. The visionary management team has led us to build industry-leading, fully-integrated capabilities in end-to-end drug R&D from pre-clinical discovery to clinical development and commercialization. The core product envafolimab is a global first and only BLA-stage, subcutaneously-injectable PD-L1 antibody that has the potential to address a global unmet medical need for the treatment of cancer as a chronic disease. With a robust I/O monotherapy and combo-therapy portfolio of more than 10 drug candidates with envafolimab as the backbone, we strive to become a leader in the chronic cancer treatment market. For more information, please visit www.3d-medicines.com.